We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

14 hedge funds and large institutions have $92K invested in Monopar Therapeutics in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.06% less ownership

Funds ownership: 0.43% → 0.37% (-0.06%)

50% less capital invested

Capital invested by funds: $182K → $92K (-$90.2K)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$19.5K
2
VF
Virtu Financial
New York
+$11K
3
Two Sigma Investments
Two Sigma Investments
New York
+$5.79K
4
UBS Group
UBS Group
Switzerland
+$4.79K
5
Millennium Management
Millennium Management
New York
+$4.18K

Top Sellers

Rank Fund Capital Flow
1
WAG
Windsor Advisory Group
Ohio
-$55.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$17.2K
3
TSS
Two Sigma Securities
New York
-$15.3K
4
HF
HRT Financial
New York
-$7K
5
TRCT
Tower Research Capital (TRC)
New York
-$43
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$16K +$19.5K +9,617 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$15.4K -$17.2K -8,486 -48%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$14K – – –
Millennium Management
4
Millennium Management
New York
$9.98K +$4.18K +2,066 +54%
GL
5
Gerber LLC
Ohio
$9.53K +$11.3K +5,601 New
VF
6
Virtu Financial
New York
$9K +$11K +5,434 New
Two Sigma Investments
7
Two Sigma Investments
New York
$4.87K +$5.79K +2,860 New
UBS Group
8
UBS Group
Switzerland
$4.05K +$4.79K +2,366 +16,900%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$3.74K +$217 +107 +5%
RRCM
10
Rappaport Reiches Capital Management
Illinois
$3.64K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$1.23K -$43 -21 -3%
Morgan Stanley
12
Morgan Stanley
New York
$544 +$324 +160 +100%
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$27 – – –
Wells Fargo
14
Wells Fargo
California
$13 – – –
WAG
15
Windsor Advisory Group
Ohio
– -$55.8K -17,995 Closed
TSS
16
Two Sigma Securities
New York
– -$15.3K -4,933 Closed
HF
17
HRT Financial
New York
– -$7K -2,616 Closed
JP Morgan Chase
18
JP Morgan Chase
New York
– -$2 -1 Closed

MNPR Hedge Fund Activity: Q4 2023 in Review

14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2023, worth a combined $92K — down 50% from $182K a quarter earlier.

Fund positioning in MNPR was balanced in Q4 2023: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $19.5K. The largest seller was Windsor Advisory Group, exiting entirely with an estimated $55.8K sold.

  • 14 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $92K of Monopar Therapeutics stock for Q4 2023, down 50% quarter-over-quarter.
  • 4 funds opened new Monopar Therapeutics positions in Q4 2023 and 4 closed out, a net change of 0 holders.
  • The largest Monopar Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $19.5K added.
  • The largest Monopar Therapeutics seller in Q4 2023 was Windsor Advisory Group, an estimated $55.8K sold.

Based on aggregated 13F filings for Q4 2023.